98 related articles for article (PubMed ID: 15845425)
1. Use of amphotericin B lipid complex in elderly patients.
Hooshmand-Rad R; Chu A; Gotz V; Morris J; Batty S; Freifeld A
J Infect; 2005 May; 50(4):277-87. PubMed ID: 15845425
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
3. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
[TBL] [Abstract][Full Text] [Related]
5. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
6. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Candida infections with amphotericin B lipid complex.
Ito JI; Hooshmand-Rad R
Clin Infect Dis; 2005 May; 40 Suppl 6():S384-91. PubMed ID: 15809924
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).
Ito JI; Chandrasekar PH; Hooshmand-Rad R
Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663
[TBL] [Abstract][Full Text] [Related]
9. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.
Chandrasekar PH; Ito JI
Clin Infect Dis; 2005 May; 40 Suppl 6():S392-400. PubMed ID: 15809925
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
15. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.
Linden PK; Coley K; Fontes P; Fung JJ; Kusne S
Clin Infect Dis; 2003 Jul; 37(1):17-25. PubMed ID: 12830404
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
Linden P; Williams P; Chan KM
Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
[TBL] [Abstract][Full Text] [Related]
17. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of amphotericin B lipid complex.
Luke RG; Boyle JA
Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
[TBL] [Abstract][Full Text] [Related]
20. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
